Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154140 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 343
- Enrollment target
NCT01154140 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 343 participants.
The verdict
NCT01154140, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 343 participants
- Enrollment target
Study Summary
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
Interventions
- DRUG treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2011-01-13 |
| Est. Completion | 2016-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154140
The ClinicalTrials.gov registry entry for NCT01154140 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which treatment is the first listed.
NCT01154140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154140 about?
NCT01154140 is a clinical study titled "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung". This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
What is the current status of trial NCT01154140?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 343 participants. The study started on 2011-01-13. Estimated completion is 2016-11-30.
What interventions are being tested in trial NCT01154140?
The interventions under investigation include: treatment (DRUG).
Who is sponsoring clinical trial NCT01154140?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.